NCT06885021View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

780

Participants

Timeline

Start Date

March 28, 2025

Primary Completion Date

May 30, 2026

Study Completion Date

June 30, 2026

Conditions
Overweight and Obesity
Interventions
DRUG

HDM1002 200mg, oral, once daily, 52 weeks

HDM1002 200mg, oral, once daily, 52 weeks

DRUG

HDM1002 400mg, oral, once daily, 52 weeks

HDM1002 400mg, oral, once daily, 52 weeks

DRUG

HDM1002 placebo, oral, once daily, 52 weeks

HDM1002 placebo, oral, once daily, 52 weeks

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY